This increased metabolic risk – most likely triggered by hypogonadism – highlights the necessity to monitor lipid metabolism in patients with prolactinoma and sets the implication for future studies to elucidate the underlying pathophysiological mechanisms for the supposed link between prolactin and lipid metabolism. Here, PRL is linked to hypogonadism.